ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in are areas of cell-based therapy, cancer, and stem cell research, development, and manufacturing of pharmaceuticals as well as production and quality control of animal semen and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; NucleoCounter SCC-100, a somatic cell counter used to measure the number of somatic cells in a milk sample; and NucleoCounter YC-100, an automated yeast cell counter used to measure the total cell count and viability of yeast cells in suspension. In addition, the company provides consumables comprising cassettes, reagents, and slides; accessories, which include cables, power supplies, software, and labware products, as well as service and validation plans. ChemoMetec A/S was incorporated in 1997 and is headquartered in Allerød, Denmark.
Stock data | 2023 | Change |
---|---|---|
Price | $63.94 | N/A |
Market Cap | $1.11B | N/A |
Shares Outstanding | 17.40M | 0.00% |
Employees | 167.00 | N/A |
Shareholder Equity | 533.04M | 49.23% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 16.81 | N/A |
P/B Ratio | 2.09 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0499 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $66.20M | N/A |
Earnings | $26.62M | N/A |
Gross Margin | 0.8897 | N/A |
Operating Margin | 0.519 | N/A |
Net income margin | 0.402 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $98.02M | N/A |
Total Debt | $1.07M | N/A |
Cash on Hand | $47.16M | N/A |
Debt to Equity | 0.0349 | -41.89% |
Cash to Debt | $44.21 | 43.71% |
Current Ratio | $4.13 | 60.89% |